Evidence map›Paper›PMID 32997949›Full record

ArticleCancer biology & therapy2020

Successful gene therapy requires targeting the vast majority of cancer cells.

Takuya Sagara, Marija Debeljak, Chapman M Wright, Nicole M Anders, Hong Liang, Michelle A Rudek, Marc Ostermeier, James R Eshleman, Yoshihisa Matsushita

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Takuya SagaraDepartments of Pathology, Johns Hopkins University, Johns Hopkins Medical Institutions , Baltimore, MD, USA.
Marija DebeljakDepartments of Pathology, Johns Hopkins University, Johns Hopkins Medical Institutions , Baltimore, MD, USA.
Chapman M WrightDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University , Baltimore, MD, USA.
Nicole M AndersOncology, Johns Hopkins University, Johns Hopkins Medical Institutions , Baltimore, MD, USA.
Hong LiangDepartments of Pathology, Johns Hopkins University, Johns Hopkins Medical Institutions , Baltimore, MD, USA.
Michelle A RudekOncology, Johns Hopkins University, Johns Hopkins Medical Institutions , Baltimore, MD, USA.
Marc OstermeierDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University , Baltimore, MD, USA.
James R EshlemanDepartments of Pathology, Johns Hopkins University, Johns Hopkins Medical Institutions , Baltimore, MD, USA.
Yoshihisa MatsushitaDepartments of Pathology, Johns Hopkins University, Johns Hopkins Medical Institutions , Baltimore, MD, USA.
Johns Hopkins University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 1993 to 2022
$54.6M
The Combinatorial Design of Protein Molecular SwitchesR01GM066972 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI OSTERMEIER, MARC A · 2003 to 2016
$4.0M
UPLC with Tandem MS for Sensitive Quantitative Analysis of Small MoleculesS10RR026824 · NCRR · JOHNS HOPKINS UNIVERSITY · PI RUDEK, MICHELLE A · 2010 to 2010
$429k
NCATS NIH HHS UL1 TR001079NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCRR NIH HHS S10 RR026824NIGMS NIH HHS R01 GM066972
6 · The paper itself

Abstract

Suicide gene therapy using gene-directed enzyme prodrug therapy (GDEPT) is based on delivering a gene-encoded enzyme to cells that converts a nontoxic prodrug into its toxic metabolite. The bystander effect is thought to compensate for inefficiencies in delivery and expression because the produced toxic metabolite can spread to adjacent non-expressing cells. The purpose of this study was to assess the significance of bystander effect in GDEPT over the long term We performed experiments using mixtures of We were able to demonstrate bystander effect in both 2D and 3D. In mice, tumors initially regressed, but they all eventually recurred including those produced from 80% We conclude that gene therapy of malignant tumors in patients using the yCD/5-FC system will require targeting well over 80% of the malignant cells, and therefore will likely require improved bystander effect or repeated treatment.

Indexed as

AnimalsFemaleGenetic TherapyHumansMiceMice, NudeSingle-Cell Analysis5-FUcytosine deaminasefluorouracilGDEPTgene-directed enzyme prodrug therapypatient-derived tumor xenograftregressionrelapse

Identifiers

PMID32997949
PMCPMC7583496
OpenAlexW3089795605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.